Biotech

All Articles

Actinogen's cortisol blocker fails stage 2 depression research

.Actinogen Medical's cortisol blocker has actually missed the key endpoint of a phase 2 study in dep...

Bivictrix makes a decision going exclusive only method to take ADC right into center

.Antibody-drug conjugates (ADCs) have actually been at the center of many a billion-dollar biobuck l...

TPG tops up funds to $580M for assets across lifestyle scientific researches

.Resource supervisor TPG, which has supported biotechs like Sionna Therapeutics and also Santa Ana B...

Merck quits period 3 TIGIT trial in lung cancer for impossibility

.Merck &amp Co.'s TIGIT program has experienced one more setback. Months after shuttering a period 3...

After a difficult year, Exscientia folds up in to Recursion

.After a year defined through pipe cuts, the variation of its own chief executive officer and also l...

Cullinan, after $25M package, return bispecific to Port

.Cullinan Therapy was wowed enough with Harbour BioMed's bispecific invulnerable activator that it h...

A more detailed consider Intense Biotech's Strong 15

.In this particular week's incident of "The Best Line," we are actually diving right into Strong Bio...

Lilly deals with stage 2 failing of tau-targeting med

.The confetti is still flying from Eli Lilly's celebration commemorating the commendation of Alzheim...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Accept to recently's Chutes &amp Ladders, our roundup of substantial management hirings, firings as...

Lykos will certainly ask FDA to reassess its own selection adhering to being rejected of MDMA therapy for post-traumatic stress disorder

.Complying with an inadequate revealing for Lykos Therapies' MDMA applicant for post-traumatic stres...